Needham Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $48
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $46 to $48.
Needham analyst Serge Belanger maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and raises the price target from $46 to $48.